8-K current report · filed Jul 1, 2026

Perspective Therapeutics, Inc. (CATX) 8-K Current Report: July 1, 2026

Item EX-99.1Item 8.01CATX overview

Short answer

Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on July 1, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events). Updated corporate presentation filed July 1, 2026 as Exhibit 99.1.

Perspective Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Updated corporate presentation filed July 1, 2026 as Exhibit 99.1
  • Presentation likely refreshes investor materials on Perspective Therapeutics’ strategy, pipeline, and corporate developments
  • Investor implications depend on substantive presentation updates, particularly clinical, regulatory, or financing information

Item EX-99.1 · Exhibit EX-99.1

  • Investor presentation outlines Perspective’s ²¹²Pb radiopharmaceutical platform, integrated isotope production, and regional direct-to-hospital delivery model
  • VMT-α-NET Phase 1/2a data highlight deepening responses and durable disease control in SSTR2-positive neuroendocrine tumors
  • VMT-α-NET safety analysis covers 68 treated patients, supporting potential registration study at the current dose
  • VMT01 and PSV359 expand the pipeline into MC1R-targeted melanoma and FAP-α solid tumors
  • Presentation supports further development but remains early-stage clinical evidence, with no definitive efficacy or approval outcome disclosed

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Perspective Therapeutics, Inc. 8-K filings

Get the next CATX 8-K as it lands

Follow CATX for push alerts, or ask the research agent what this filing means.